Alberta Palliative Patient Successfully Undergoes First Legal Psychedelic-Assisted Therapy in Alberta, Initial Outcomes Exceed Expectations Post published:January 6, 2021 Post category:Press Release
Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities Post published:January 6, 2021 Post category:Press Release
Mindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of Potential Clinical Use Cases Including Micro-Dosing Post published:January 6, 2021 Post category:Press Release
Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products Post published:January 6, 2021 Post category:Press Release
Lobe Sciences Announces Further Upsizing and Second Closing of Non-Brokered Private Placement Post published:January 6, 2021 Post category:Press Release
COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferences Post published:January 6, 2021 Post category:Press Release
Psyched Wellness Commences Antioxidant and Anti-Inflammatory Study on Muscimol Post published:January 6, 2021 Post category:Press Release
Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research Post published:January 6, 2021 Post category:Press Release
MEC announces letter of intent to acquire Albert Labs, a European psychedelic drug researcher & developer Post published:January 5, 2021 Post category:Press Release
Field Trip Health Ltd. Announces Closing of Bought Deal Financing Post published:January 5, 2021 Post category:Press Release